Immune Modulation with Sulfasalazine Attenuates Immunopathogenesis but Enhances Macrophage-Mediated Fungal Clearance during Pneumonia

English version České info

Although T cells are critical for host defense against respiratory fungal infections, they also contribute to the immunopathogenesis of Pneumocystis pneumonia (PcP). However, the precise downstream effector mechanisms by which T cells mediate these diverse processes are undefined. In the current study the effects of immune modulation with sulfasalazine were evaluated in a mouse model of PcP-related Immune Reconstitution Inflammatory Syndrome (PcP-IRIS). Recovery of T cell-mediated immunity in Pneumocystis-infected immunodeficient mice restored host defense, but also initiated the marked pulmonary inflammation and severe pulmonary function deficits characteristic of IRIS. Sulfasalazine produced a profound attenuation of IRIS, with the unexpected consequence of accelerated fungal clearance. To determine whether macrophage phagocytosis is an effector mechanism of T cell-mediated Pneumocystis clearance and whether sulfasalazine enhances clearance by altering alveolar macrophage phagocytic activity, a novel multispectral imaging flow cytometer-based method was developed to quantify the phagocytosis of Pneumocystis in vivo. Following immune reconstitution, alveolar macrophages from PcP-IRIS mice exhibited a dramatic increase in their ability to actively phagocytose Pneumocystis. Increased phagocytosis correlated temporally with fungal clearance, and required the presence of CD4⁺ T cells. Sulfasalazine accelerated the onset of the CD4⁺ T cell-dependent alveolar macrophage phagocytic response in PcP-IRIS mice, resulting in enhanced fungal clearance. Furthermore, sulfasalazine promoted a TH2-polarized cytokine environment in the lung, and sulfasalazine-enhanced phagocytosis of Pneumocystis was associated with an alternatively activated alveolar macrophage phenotype. These results provide evidence that macrophage phagocytosis is an important in vivo effector mechanism for T cell-mediated Pneumocystis clearance, and that macrophage phenotype can be altered to enhance phagocytosis without exacerbating inflammation. Immune modulation can diminish pulmonary inflammation while preserving host defense, and has therapeutic potential for the treatment of PcP-related immunopathogenesis.

Vyšlo v časopise: Immune Modulation with Sulfasalazine Attenuates Immunopathogenesis but Enhances Macrophage-Mediated Fungal Clearance during Pneumonia. PLoS Pathog 6(8): e32767. doi:10.1371/journal.ppat.1001058
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.ppat.1001058

Souhrn

Zdroje

1. SantosJ

PalaciosR

RuizJ

GonzalezM

MarquezM

2005 Study of patients diagnosed with advanced HIV in the HAART era—OMEGA Cohort. Int J STD AIDS 16 252 255

2. ForrestDM

SeminariE

HoggRS

YipB

RaboudJ

1998 The incidence and spectrum of AIDS-defining illnesses in persons treated with antiretroviral drugs. Clin Infect Dis 27 1379 1385

3. StaikowskyF

LafonB

GuidetB

DenisM

MayaudC

1993 Mechanical ventilation for Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome. Is the prognosis really improved? Chest 104 756 762

4. ArendSM

KroonFP

van't WoutJW

1995 Pneumocystis carinii pneumonia in patients without AIDS, 1980 through 1993. An analysis of 78 cases. Arch Intern Med 155 2436 2441

5. KaurN

MahlTC

2004 Pneumocystis carinii pneumonia with oral candidiasis after infliximab therapy for Crohn's disease. Dig Dis Sci 49 1458 1460

6. SepkowitzKA

BrownAE

ArmstrongD

1995 Pneumocystis carinii pneumonia without acquired immunodeficiency syndrome. More patients, same risk. Arch Intern Med 155 1125 1128

7. MorrisA

SciurbaFC

LebedevaIP

GithaigaA

ElliottWM

2004 Association of Chronic Obstructive Pulmonary Disease Severity and Pneumocystis Colonization. Am J Respir Crit Care Med 170 408 413

8. BenfieldTL

van SteenwijkR

NielsenTL

DichterJR

LipschikGY

1995 Interleukin-8 and eicosanoid production in the lung during moderate to severe Pneumocystis carinii pneumonia in AIDS: a role of interleukin-8 in the pathogenesis of P. carinii pneumonia. Respir Med 89 285 290

9. JensenBN

LisseIM

GerstoftJ

BorgeskovS

SkinhojP

1991 Cellular profiles in bronchoalveolar lavage fluid of HIV-infected patients with pulmonary symptoms: relation to diagnosis and prognosis. AIDS 5 527 533

10. LimperAH

OffordKP

SmithTF

MartinWJ

1989 Pneumocystis carinii pneumonia. Differences in lung parasite number and inflammation in patients with and without AIDS. Am Rev Respir Dis 140 1204 1209

11. LipschikGY

DoerflerME

KovacsJA

TravisWD

AndrawisVA

1993 Leukotriene B4 and interleukin-8 in human immunodeficiency virus-related pulmonary disease. Chest 104 763 769

12. MasonGR

HashimotoCH

DickmanPS

FouttyLF

CobbCJ

1989 Prognostic implications of bronchoalveolar lavage neutrophilia in patients with Pneumocystis carinii pneumonia and AIDS. Am Rev Respir Dis 139 1336 1342

13. SmithRL

El-SadrWM

LewisML

1988 Correlation of bronchoalveolar lavage cell populations with clinical severity of Pneumocystis carinii pneumonia. Chest 93 60 64

14. BenfieldTL

VestboJ

JungeJ

NielsenTL

JensenAB

1995 Prognostic value of interleukin-8 in AIDS-associated Pneumocystis carinii pneumonia. Am J Respir Crit Care Med 151 1058 1062

15. VahidB

BibboM

MarikPE

2007 Role of CD8 lymphocytes and neutrophilic alveolitis in Pneumocystis jiroveci pneumonia. Scandinavian Journal of Infectious Diseases 39 612 614

16. BarrySM

LipmanMC

DeeryAR

JohnsonMA

JanossyG

2002 Immune reconstitution pneumonitis following Pneumocystis carinii pneumonia in HIV-infected subjects. HIV Med 3 207 211

17. DoreGJ

LiY

McDonaldA

ReeH

KaldorJM

2002 Impact of highly active antiretroviral therapy on individual AIDS-defining illness incidence and survival in Australia. J Acquir Immune Defic Syndr 29 388 395

18. WuAK

ChengVC

TangBS

HungIF

LeeRA

2004 The unmasking of Pneumocystis jiroveci pneumonia during reversal of immunosuppression: case reports and literature review. BMC Infect Dis 4 57

19. SharmaS

NadrousHF

PetersSG

TefferiA

LitzowMR

2005 Pulmonary complications in adult blood and marrow transplant recipients: autopsy findings. Chest 128 1385 1392

20. SlivkaA

WenPY

SheaWM

LoefflerJS

1993 Pneumocystis carinii pneumonia during steroid taper in patients with primary brain tumors. Am J Med 94 216 219

21. MansharamaniNG

BalachandranD

VernovskyI

GarlandR

KozielH

2000 Peripheral blood CD4 + T-lymphocyte counts during Pneumocystis carinii pneumonia in immunocompromised patients without HIV infection. Chest 118 712 720

22. BachelezH

SchremmerB

CadranelJ

MoulyF

SarfatiC

1997 Fulminant Pneumocystis carinii pneumonia in 4 patients with dermatomyositis. Arch Intern Med 157 1501 1503

23. SepkowitzKA

1993 Pneumocystis carinii pneumonia in patients without AIDS. Clin Infect Dis 17 Suppl 2 S416 S422

24. KovacsJA

HiemenzJW

MacherAM

StoverD

MurrayHW

1984 Pneumocystis carinii pneumonia: a comparison between patients with the acquired immunodeficiency syndrome and patients with other immunodeficiencies. Ann Intern Med 100 663 671

25. HoriS

CarvalhoTL

DemengeotJ

2002 CD25+CD4+ regulatory T cells suppress CD4+ T cell-mediated pulmonary hyperinflammation driven by Pneumocystis carinii in immunodeficient mice. Eur J Immunol 32 1282 1291

26. RothsJB

SidmanCL

1992 Both immunity and hyperresponsiveness to Pneumocystis carinii result from transfer of CD4+ but not CD8+ T cells into severe combined immunodeficiency mice. J Clin Invest 90 673 678

27. SwainSD

MeissnerNN

HarmsenAG

2006 CD8 T cells modulate CD4 T-cell and eosinophil-mediated pulmonary pathology in Pneumocystis pneumonia in B-cell-deficient mice. Am J Pathol 168 466 475

28. WrightTW

GigliottiF

FinkelsteinJN

McBrideJT

AnCL

1999 Immune-mediated inflammation directly impairs pulmonary function, contributing to the pathogenesis of Pneumocystis carinii pneumonia. J Clin Invest 104 1307 1317

29. WrightTW

JohnstonCJ

HarmsenAG

FinkelsteinJN

1999 Chemokine gene expression during Pneumocystis carinii-driven pulmonary inflammation. Infect Immun 67 3452 3460

30. WrightTW

NotterRH

WangZ

HarmsenAG

GigliottiF

2001 Pulmonary inflammation disrupts surfactant function during Pneumocystis carinii pneumonia. Infect Immun 69 758 764

31. BhagwatSP

GigliottiF

XuH

WrightTW

2006 Contribution of T cell subsets to the pathophysiology of Pneumocystis-related immunorestitution disease. Am J Physiol Lung Cell Mol Physiol 291 L1256 L1266

32. RothsJB

SidmanCL

1993 Single and combined humoral and cell-mediated immunotherapy of Pneumocystis carinii pneumonia in immunodeficient scid mice. Infect Immun 61 1641 1649

33. SwainSD

HanS

HarmsenA

ShampenyK

HarmsenAG

2007 Pulmonary Hypertension Can Be a Sequela of Prior Pneumocystis Pneumonia. Am J Pathol 171 790 799

34. O'DellJR

PetersenK

LeffR

PalmerW

SchnedE

2006 Etanercept in combination with sulfasalazine, hydroxychloroquine, or gold in the treatment of rheumatoid arthritis. J Rheumatol 33 213 218

35. PloskerGL

CroomKF

2005 Sulfasalazine: a review of its use in the management of rheumatoid arthritis. Drugs 65 1825 1849

36. BrookesMJ

GreenJR

2004 Maintenance of remission in Crohn's disease: current and emerging therapeutic options. Drugs 64 1069 1089

37. LiptayS

BachemM

HackerG

AdlerG

DebatinKM

1999 Inhibition of nuclear factor kappa B and induction of apoptosis in T-lymphocytes by sulfasalazine. Br J Pharmacol 128 1361 1369

38. WangJ

GigliottiF

MaggirwarS

JohnstonC

FinkelsteinJN

2005 Pneumocystis carinii activates the NF-kappaB signaling pathway in alveolar epithelial cells. Infect Immun 73 2766 2777

39. WeberCK

LiptayS

WirthT

AdlerG

SchmidRM

2000 Suppression of NF-kappaB activity by sulfasalazine is mediated by direct inhibition of IkappaB kinases alpha and beta. Gastroenterology 119 1209 1218

40. WahlC

LiptayS

AdlerG

SchmidRM

1998 Sulfasalazine: a potent and specific inhibitor of nuclear factor kappa B. J Clin Invest 101 1163 1174

41. EvansSE

HahnPY

McCannF

KottomTJ

PavlovicZV

2005 Pneumocystis cell wall beta-glucans stimulate alveolar epithelial cell chemokine generation through nuclear factor-kappaB-dependent mechanisms. Am J Respir Cell Mol Biol 32 490 497

42. LebronF

VassalloR

PuriV

LimperAH

2003 Pneumocystis carinii cell wall beta-glucans initiate macrophage inflammatory responses through NF-kappaB activation. J Biol Chem 278 25001 25008

43. ZhangJ

ZhuJ

ImrichA

CushionM

KinaneTB

2004 Pneumocystis activates human alveolar macrophage NF-kappaB signaling through mannose receptors. Infect Immun 72 3147 3160

44. MartinezFO

HelmingL

GordonS

2008 Macrophage activation and polarization. Annu Rev Immuno 27 451 483

45. GordonS

2007 The macrophage: past, present and future. Eur J Immunol 37 Suppl 1 S9 17

46. ChengVC

HungIF

WuAK

TangBS

ChuCM

2004 Lymphocyte surge as a marker for immunorestitution disease due to Pneumocystis jiroveci pneumonia in HIV-negative immunosuppressed hosts. Eur J Clin Microbiol Infect Dis 23 512 514

47. ChenCS

BoeckhM

SeidelK

ClarkJG

KansuE

2003 Incidence, risk factors, and mortality from pneumonia developing late after hematopoietic stem cell transplantation. Bone Marrow Transplant 32 515 522

48. GanHT

ChenYQ

OuyangQ

2005 Sulfasalazine inhibits activation of nuclear factor-kappaB in patients with ulcerative colitis. J Gastroenterol Hepatol 20 1016 1024

49. BaggottJE

MorganSL

HaT

VaughnWH

HineKJ

1992 Inhibition of folate-dependent enzymes by non-steroidal anti-infalmmatory drugs. Biochem J 282 197 202

50. GadangiP

LongakerM

NaimeD

LevinRI

RechtPA

1996 The anti-inflammatory mechanism of sulfasalazine is related to adenosine release at inflamed sites. J Immunol 156 1937 1941

51. LukashevD

OhtaA

ApasovS

ChenJF

SitkovskyM

2004 Cutting Edge: Physiologic Attenuation of Proinflammatory Transcription by the Gs Protein-Coupled A2A Adenosine Receptor In Vivo. J Immunol 173 21 24

52. RousseauxC

LefebvreB

DubuquoyL

LefebvreP

RomanoO

2005 Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-{gamma}. J Exp Med 201 1205 1215

53. SalhB

AssiK

HuangS

O'BrienL

SteinbrecherU

2002 Dissociated ROS production and ceramide generation in sulfasalazine-induced cell death in Raw 264.7 cells. J Leukoc Biol 72 790 799

54. OshikawaK

SugiyamaY

2003 Regulation of toll-like receptor 2 and 4 gene expression in murine alveolar macrophages. Exp Lung Res 29 401 412

55. HaskoG

SzaboC

NemethZH

DeitchEA

2001 Sulphasalazine inhibits macrophage activation: inhibitory effects on inducible nitric oxide synthase expression, interleukin-12 production and major histocompatibility complex II expression. Immunology 103 473 478

56. WangJ

GigliottiF

BhagwatSP

MaggirwarSB

WrightTW

2007 Pneumocystis stimulates MCP-1 production by alveolar epithelial cells through a JNK-dependent mechanism. Am J Physiol Lung Cell Mol Physiol 292 L1495 L1505

57. CosteA

DubourdeauM

LinasMD

CassaingS

LepertJC

2003 PPARgamma promotes mannose receptor gene expression in murine macrophages and contributes to the induction of this receptor by IL-13. Immunity 19 329 339

58. CosteA

LaganeC

FilipeC

AuthierH

GalesA

2008 IL-13 attenuates gastrointestinal candidiasis in normal and immunodeficient RAG-2(-/-) mice via peroxisome proliferator-activated receptor-gamma activation. J Immunol 180 4939 4947

59. GalesA

ConducheA

BernadJ

LefevreL

OlagnierD

2010 PPARgamma controls dectin-1 expression required for host antifungal defense against Candida albicans. PLoS Pathog 6(1) e1000714

60. HunterMM

WangA

ParharKS

JohnstonMJ

VanRN

2010 In vitro-derived alternatively activated macrophages reduce colonic inflammation in mice. Gastroenterology 138 1395 1405

61. GautP

DaarES

1999 Editorial response: Prophylaxis for Pneumocystis carinii pneumonia—an evolving tale of two populations. Clin Infect Dis 29 784 786

62. BhagwatSP

WrightTW

GigliottiF

2010 Anti-CD3 antibody decreases inflammation and improves outcome in a murine model of Pneumocystis pneumonia. J Immunol 184 497 502

63. EzekowitzRA

WilliamsDJ

KozielH

ArmstrongMY

WarnerA

1991 Uptake of Pneumocystis carinii mediated by the macrophage mannose receptor. Nature 351 155 158

64. ForteM

RaheluM

StubberfieldC

TomkinsL

PithieA

1991 In-vitro interaction of human macrophages with Pneumocystis carinii. Int J Exp Pathol 72 589 598

65. KozielH

EichbaumQ

KruskalBA

PinkstonP

RogersRA

1998 Reduced binding and phagocytosis of Pneumocystis carinii by alveolar macrophages from persons infected with HIV-1 correlates with mannose receptor downregulation. J Clin Invest 102 1332 1344

66. LasburyME

LinP

TschangD

DurantPJ

LeeCH

2004 Effect of bronchoalveolar lavage fluid from Pneumocystis carinii-infected hosts on phagocytic activity of alveolar macrophages. Infect Immun 72 2140 2147

67. LimperAH

StandingJE

HoyteJS

1996 The role of alveolar macrophages in Pneumocystis carinii elimination from the lower respiratory tract. J Eukaryot Microbiol 43 12S

68. MasurH

JonesTC

1978 The interaction in vitro of Pneumocystis carinii with macrophages and L-cells. J Exp Med 147 157 170

69. SteeleC

MarreroL

SwainS

HarmsenAG

ZhengM

2003 Alveolar macrophage-mediated killing of Pneumocystis carinii f. sp. muris involves molecular recognition by the Dectin-1 beta-glucan receptor. J Exp Med 198 1677 1688

70. ZhangJ

ZhuJ

BuX

CushionM

KinaneTB

2005 Cdc42 and RhoB activation are required for mannose receptor-mediated phagocytosis by human alveolar macrophages. Mol Biol Cell 16 824 834

71. BaskervilleA

DowsettAB

CookRW

DennisMJ

CranageMP

1991 Pneumocystis carinii pneumonia in simian immunodeficiency virus infection: immunohistological and scanning and transmission electron microscopical studies. J Pathol 164 175 184

72. ChenW

MillsJW

HarmsenAG

1992 Development and resolution of Pneumocystis carinii pneumonia in severe combined immunodeficient mice: a morphological study of host inflammatory responses. Int J Exp Pathol 73 709 720

73. WehleK

BlankeM

KoenigG

PfitzerP

1991 The cytological diagnosis of Pneumocystis carinii by fluorescence microscopy of Papanicolaou stained bronchoalveolar lavage specimens. Cytopathology 2 113 120

74. WehleK

SchirmerM

Dunnebacke-HinzJ

KupperT

PfitzerP

1993 Quantitative differences in phagocytosis and degradation of Pneumocystis carinii by alveolar macrophages in AIDS and non-HIV patients in vivo. Cytopathology 4 231 236

75. EmpeyKM

HollifieldM

SchuerK

GigliottiF

GarvyBA

2004 Passive immunization of neonatal mice against Pneumocystis carinii f. sp. muris enhances control of infection without stimulating inflammation. Infect Immun 72 6211 6220

76. WeaverT

HallCL

KachelDL

WardRP

WilliamsMD

1996 Assessment of in vivo attachment/phagocytosis by alveolar macrophages. J Immunol Methods 193 149 156

77. LimperAH

HoyteJS

StandingJE

1997 The role of alveolar macrophages in Pneumocystis carinii degradation and clearance from the lung. J Clin Invest 99 2110 2117

78. WrightTW

PryhuberGS

ChessPR

WangZ

NotterRH

2004 TNF receptor signaling contributes to chemokine secretion, inflammation, and respiratory deficits during Pneumocystis pneumonia. J Immunol 172 2511 2521

79. GeorgeTC

BasijiDA

HallBE

LynchDH

OrtynWE

2004 Distinguishing modes of cell death using the ImageStream multispectral imaging flow cytometer. Cytometry A 59 237 245

80. OrtynWE

HallBE

GeorgeTC

FrostK

BasijiDA

2006 Sensitivity measurement and compensation in spectral imaging. Cytometry A 69 852 862

81. WellsJ

GigliottiF

Simpson-HaidarisPJ

HaidarisCG

2004 Epitope mapping of a protective monoclonal antibody against Pneumocystis carinii with shared reactivity to Streptococcus pneumoniae surface antigen PspA. Infect Immun 72 1548 1556

82. GeorgeTC

FanningSL

Fitzgeral-BocarslyP

MedeirosRB

HighfillS

2006 Quantitative measurement of nuclear translocation events using similarity analysis of multispectral cellular images obtained in flow. Journal of Immunological Methods 311 117 129

83. MegjugoracNJ

JacobsES

IzaguirreAG

GeorgeTC

GuptaG

2007 Image-Based Study of Interferongenic Interactions between Plasmacytoid Dendritic Cells and HSV-Infected Monocyte-Derived Dendritic Cells*. Immunological Investigations 36 739 761